Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

EpiATLAS - a reference for human epigenomic research.

bioRxiv : the preprint server for biology·2026

Same author

Gradient of CD79B expression in diffuse large B-cell lymphoma corresponds to stages of germinal center B-cell differentiation.

Haematologica·2026

Same author

A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.

Blood cancer discovery·2026

Same author

LCR-modules: a collection of workflows for cancer genome analysis.

Bioinformatics (Oxford, England)·2026

Same author

A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).

Blood neoplasia·2026

Same author

Regulatory factor X 7 limits Myc activity during B cell activation and suppresses Myc-dependent lymphomagenesis.

Nature immunology·2026

Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026

Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026

Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026

Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026

Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026

Same journal

A step toward streamlining HIT diagnosis.

Blood·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 13, 2026

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

Progress toward inducing immunologic tolerance to factor VIII.

David W Scott¹, Kathleen P Pratt, Carol H Miao

¹Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20892, USA. scottd43@gmail.com

|March 19, 2013

Summary

This summary is machine-generated.

Developing new methods to induce immune tolerance to factor VIII (FVIII) is crucial for hemophilia A patients who develop inhibitors. Research is exploring novel, cost-effective strategies beyond traditional immune tolerance induction (ITI).

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Related Experiment Videos

Last Updated: May 13, 2026

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Area of Science:

Immunology
Hematology
Biotechnology

Background:

* Hemophilia A patients treated with factor VIII (FVIII) often develop neutralizing anti-FVIII antibodies, termed inhibitors.
* These inhibitors impede FVIII's procoagulant function, complicating treatment.
* Current immune tolerance induction (ITI) is costly and less effective for high-titer inhibitors.

Purpose of the Study:

* To review recent advancements in understanding and suppressing anti-FVIII immune responses.
* To highlight novel, potentially less costly methods for inducing FVIII tolerance.
* To discuss strategies for managing existing inhibitors and preventing future immune responses.

Main Methods:

* Analysis of animal model studies investigating novel tolerance induction methods.
* Examination of human donor blood samples to identify anti-FVIII T-cell epitopes.
* Mechanistic studies using human T-cell clones and lines.

Main Results:

* Progress in understanding mechanisms of allo- and autoimmune responses to FVIII.
* Identification of immunodominant T-cell epitopes in FVIII.
* Animal models suggest novel, cost-effective tolerance induction strategies.

Conclusions:

* Recent research offers promising avenues for lowering anti-FVIII immune responses.
* Novel strategies may provide more accessible and effective tolerance induction for hemophilia A patients.
* Continued research aims to promote durable, functional immune tolerance to FVIII.